Physician profile
Altaf Jan
NPI 1922072404
$1,948.30
in general payments reported to CMS, 2019-2025
13 companies · $609 in 2025
The $609 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2022: $323 · 2023: $278 · 2024: $323 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $566.18 | 2022-2025 | |
| Abbvie INC. | $329.33 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $327.15 | 2025 | |
| Gilead Sciences, INC. | $178.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.80 | 2019-2022 | |
| Celltrion USA INC. | $122.31 | 2025 | Zymfentra |
| Olympus America INC. | $70.36 | 2023-2024 | Evis Exera III Colonovideoscope, Endoclot Sis, Gastrointestinal Videoscope |
| Ardelyx, INC. | $56.23 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.26 | 2024-2025 | Xifaxan, Plenvu |
| Qol Medical, LLC | $22.12 | 2019 | |
| Pfizer INC. | $19.95 | 2025 | |
| Allergan, INC. | $19.92 | 2019 | |
| Janssen Biotech, INC. | $16.47 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Altaf Jan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.